Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

The US Food and Drug Administration has fully approved a new COVID vaccine option specifically targeting high-risk individuals, including seniors. The protein-based Nuvaxovid vaccine, produced by ...

"The FDA will approve vaccines for high-risk persons and, at the same time, demand robust, gold-standard data on persons at ...

(Reuters) -Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 ...

The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

In the NEJM article, the FDA notes that covid booster uptake has been low in the US, with less than a quarter of people ...

Federal health officials will no longer routinely approve annual COVID-19 shots for younger adults and children who are ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...